GTR Home > Conditions/Phenotypes > Autoimmune lymphoproliferative syndrome type 1, autosomal recessive

Summary

Autoimmune lymphoproliferative syndrome (ALPS) is an inherited disorder in which the body cannot properly regulate the number of immune system cells (lymphocytes). ALPS is characterized by the production of an abnormally large number of lymphocytes (lymphoproliferation). Accumulation of excess lymphocytes results in enlargement of the lymph nodes (lymphadenopathy), the liver (hepatomegaly), and the spleen (splenomegaly). People with ALPS have an increased risk of developing cancer of the immune system cells (lymphoma) and may also be at increased risk of developing other types of cancers. Autoimmune disorders are also characteristic of ALPS. Autoimmune disorders occur when the immune system malfunctions and attacks the body's tissues and organs. Most of the autoimmune disorders associated with ALPS damage blood cells. For example, the immune system may attack red blood cells (autoimmune hemolytic anemia), white blood cells (autoimmune neutropenia) or platelets (autoimmune thrombocytopenia). Other autoimmune disorders that may occur in people with ALPS ... damage the kidneys (glomerulonephritis), liver (autoimmune hepatitis), eyes (uveitis), nerves (Guillain-Barre syndrome), or connective tissues, the material that provides strength and flexibility to structures throughout the body (systemic lupus erythematosus). Individuals with ALPS may develop skin rashes or hardened skin with painful lumps or patches (panniculitis). Other signs and symptoms such as arthritis, inflammation of blood vessels (vasculitis), mouth sores (oral ulcers), or an early loss of ovarian function (premature ovarian failure) may also occur in this disorder. Affected individuals may also develop neurological damage (organic brain syndrome) with symptoms that may include headaches, seizures, or a loss of intellectual functions (dementia). ALPS is categorized into several types based mainly on the genetic cause. In the most common form of the disorder, lymphoproliferation generally becomes apparent during childhood. Enlargement of the lymph nodes and spleen frequently occur in affected individuals. Autoimmune disorders typically develop later in life, most frequently as a combination of hemolytic anemia and thrombocytopenia called Evans syndrome. People with this form of ALPS have a greatly increased risk of developing lymphoma compared with the general population. Other types of ALPS are very rare. In some affected individuals, severe lymphoproliferation begins around the time of birth, and autoimmune diseases and lymphoma develop at an early age. People with this pattern of signs and symptoms generally do not live beyond childhood. One form of ALPS involves lymphoproliferation and the tendency to develop systemic lupus erythematosus. Individuals with this form of the disorder do not have an enlarged spleen. [from GHR] more

Available tests

1 test is in the database for this condition. See lab offering the test.

Check Related conditions for additional relevant tests.

Clinical features

Help
  • Splenomegaly
  • Defective lymphocyte apoptosis
  • Chronic noninfectious lymphadenopathy
  • Increased number of peripheral CD3+ T cells
  • Increased number of CD4-/CD8- T cells expressing alpha/beta T-cell receptors
  • Increased proportion of HLA DR+ and CD57+ T cells
  • Reduced delayed hypersensitivity
  • Increased IgG level
  • Vasculitis
  • Urticaria
  • Eosinophilia
  • Autoimmune hemolytic anemia
  • Iron deficiency anemia
  • Autoimmune neutropenia
  • Autoimmune thrombocytopenia
  • Hepatomegaly
  • Follicular hyperplasia
  • Rheumatoid factor positive
  • Increased IgA level
  • Smooth muscle antibody positivity
  • Antineutrophil antibody positivity
  • Platelet antibody positive
  • Antinuclear antibody positivity
  • Increased IgM level
  • Antiphospholipid antibody positivity
  • Coombs-positive hemolytic anemia
Show all (26)

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Write to the Help Desk